Lhasa Limited shared knowledge shared progress
  • Publisher:
    Lhasa Limited
  • Publication Date:
    Sep 2014
  • Reference:
  • DOI:
  • PMID:
  • Publication Type:
  • Related Products:
  • Scientific Area:
  • Endpoint:
  • Industry Type:
  • Related event:

Explaining and demonstrating successful use of purging and depletion strategies to control mutagenic impurities.pdf

pdf fileTeasdale A;

Dr. Andrew Teasdale of AstraZeneca, has developed an approach for the assessment of the likelihood of an impurity remaining in the API. In this presentation, Andrew introduces this topic and outlines the progress to date with this approach.

Presented by Andrew Teasdale as part of the 2014 virtual ICGM series; 26th November 2014.


© 2019 Lhasa Limited | Registered office: Granary Wharf House, 2 Canal Wharf, Leeds, LS11 5PS, UK Tel: +44 (0)113 394 6020
VAT number 396 8737 77 | Lhasa Limited is registered as a charity (290866)| Company Registration Number 01765239 (England and Wales).

Thanks to QuestionPro's generosity, we now have survey software that powers our data intelligence.